Mark Howard Snyder insider trades

Open-market stock purchases and sales by Mark Howard Snyder, SVP, CHIEF LEGAL OFFICER at Halozyme Therapeutics, Inc, from SEC Form 4 filings since Jan 3, 2022.

Recent trades

DateStockTradeValue
Jun 12, 2026HALO Halozyme Therapeutics, IncSold (not open market)$189K
Jun 12, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
Feb 23, 2026HALO Halozyme Therapeutics, IncSold (not open market)$267K
Feb 23, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
Feb 20, 2026HALO Halozyme Therapeutics, IncSold (not open market)$204K
Feb 20, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
Feb 16, 2026HALO Halozyme Therapeutics, IncSold (not open market)$206K
Feb 16, 2026HALO Halozyme Therapeutics, IncSold (not open market)$515K
Feb 16, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
Feb 16, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
Feb 9, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
Feb 9, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
Feb 9, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
Feb 9, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
Feb 9, 2026HALO Halozyme Therapeutics, IncBought (not open market)—
Jan 3, 2026HALO Halozyme Therapeutics, IncSold (not open market)$298K
Jan 3, 2026HALO Halozyme Therapeutics, IncBought (not open market)—

Companies traded

  • HALO Halozyme Therapeutics, Inc: other filings, last Jun 12, 2026

Get free alerts when Mark Howard Snyder files a new trade →